Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Status:
Not yet recruiting
Trial end date:
2026-10-06
Target enrollment:
Participant gender:
Summary
This first-in-human study will be counducted to evaluate the safety, tolerability,
pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive
Locally Advanced or Metastatic Solid Tumors.